risankizumab 🐶 Veterinary Use | Indications/Contra | FAERs-F | FAERs-M | Orange Bk | PK/Tox | Related Drugs | BioActivity |

Stem definitionDrug idCAS RN
humanized origin 5337 1612838-76-2

Description:

MoleculeDescription

Synonyms:

  • risankizumab
  • skyrizi
  • BI655066
  • 655066-01
  • ABBV-066
  • BI-655066
  • risankizumab-rzaa
  • risankizumab (genetical recombination)
Skyrizi is a medicine used to treat plaque psoriasis, a disease causing red, scaly patches on the skin. Indicated for the treatment of moderate-to-severe plaque psoriasis in adults who are candidates for systemic therapy or phototherapy
  • Molecular weight:
  • Formula:
  • CLOGP:
  • LIPINSKI: None
  • HAC: None
  • HDO: None
  • TPSA:
  • ALOGS:
  • ROTB: None

Drug dosage:

DoseUnitRoute
1.67 mg P

ADMET properties:

None

Predicted pharmacokinetic/toxicological properties (PK-AZ):

None

Approvals:

DateAgencyCompanyOrphan
March 26, 2019 PMDA AbbVie Deutschland GmbH & Co KG
April 23, 2019 FDA AbbVie INC
April 26, 2019 EMA AbbVie Deutschland GmbH & Co KG

FDA Adverse Event Reporting System (Female)

MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event
COVID-19 219.34 16.48 185 12579 168658 90447025
Maternal exposure during pregnancy 156.17 16.48 221 12543 359842 90255841
Surgery 147.68 16.48 87 12677 44800 90570883
Therapy interrupted 136.33 16.48 86 12678 50022 90565661
Death 131.11 16.48 232 12532 456319 90159364
Drug ineffective 126.55 16.48 453 12311 1383845 89231838
Product storage error 119.72 16.48 58 12706 20183 90595500
Intestinal obstruction 109.26 16.48 67 12697 37064 90578619
Ileocaecal resection 96.67 16.48 21 12743 531 90615152
Psoriasis 94.28 16.48 110 12654 147644 90468039
Inflammatory bowel disease 86.05 16.48 31 12733 5140 90610543
Breast cancer female 77.16 16.48 39 12725 14847 90600836
Abortion spontaneous 73.67 16.48 61 12703 53995 90561688
Urinary tract infection 68.53 16.48 140 12624 305492 90310191
Faecal calprotectin increased 66.71 16.48 24 12740 3963 90611720
Stoma creation 58.13 16.48 11 12753 135 90615548
Illness 57.26 16.48 64 12700 81905 90533778
Small intestinal obstruction 54.13 16.48 35 12729 21199 90594484
Ileal stenosis 49.42 16.48 17 12747 2461 90613222
Paternal exposure during pregnancy 48.70 16.48 11 12753 334 90615349
Device issue 48.06 16.48 37 12727 29500 90586183
Abdominal pain 47.78 16.48 143 12621 395578 90220105
Skin burning sensation 44.35 16.48 30 12734 19581 90596102
Large intestinal stenosis 41.66 16.48 15 12749 2482 90613201
Breast cancer 41.05 16.48 44 12720 53717 90561966
Erythema nodosum 38.72 16.48 18 12746 5706 90609977
Product temperature excursion issue 38.19 16.48 11 12753 892 90614791
Therapeutic response shortened 37.97 16.48 29 12735 22850 90592833
Arthralgia 37.84 16.48 212 12552 778310 89837373
Rheumatoid arthritis 36.97 16.48 4 12760 362610 90253073
Stenosis 36.58 16.48 13 12751 2071 90613612
Intestinal resection 35.77 16.48 14 12750 2913 90612770
Cerebrovascular accident 34.26 16.48 62 12702 123471 90492212
Erythema 33.66 16.48 89 12675 229157 90386526
Abdominal abscess 33.55 16.48 16 12748 5371 90610312
Unevaluable event 33.54 16.48 40 12724 54808 90560875
Hospitalisation 32.65 16.48 62 12702 128038 90487645
Pustule 32.47 16.48 13 12751 2870 90612813
Therapeutic product effect incomplete 32.33 16.48 79 12685 193817 90421866
Therapy cessation 31.79 16.48 32 12732 36329 90579354
Skin disorder 31.53 16.48 32 12732 36674 90579009
Pruritus 30.02 16.48 153 12611 541372 90074311
SARS-CoV-2 test positive 29.99 16.48 19 12745 11109 90604574
Wound 29.26 16.48 4 12760 302976 90312707
Drug interaction 28.30 16.48 3 12761 276450 90339233
Stomatitis 28.07 16.48 3 12761 274695 90340988
Live birth 27.62 16.48 44 12720 79063 90536620
Colectomy 27.25 16.48 12 12752 3355 90612328
Face oedema 27.04 16.48 24 12740 23294 90592389
Terminal ileitis 26.59 16.48 9 12755 1241 90614442
Infusion related reaction 26.18 16.48 13 12751 416767 90198916
Faecal calprotectin abnormal 26.11 16.48 6 12758 197 90615486
Gastrointestinal wall thickening 25.34 16.48 10 12754 2127 90613556
Intestinal dilatation 24.58 16.48 10 12754 2300 90613383
Dermatitis exfoliative generalised 24.24 16.48 13 12751 5580 90610103
Pyoderma gangrenosum 24.02 16.48 12 12752 4452 90611231
Anastomotic ulcer 23.91 16.48 7 12757 601 90615082
Palmoplantar pustulosis 23.85 16.48 7 12757 607 90615076
Device defective 23.70 16.48 11 12753 3475 90612208
Confusional state 22.85 16.48 13 12751 386192 90229491
Impaired healing 22.83 16.48 3 12761 234196 90381487
Ileostomy 22.67 16.48 9 12755 1945 90613738
Neuroendocrine tumour of the lung 22.27 16.48 4 12760 36 90615647
Mucous stools 22.14 16.48 12 12752 5259 90610424
Skin plaque 21.93 16.48 15 12749 9960 90605723
Myalgia 21.75 16.48 64 12700 175061 90440622
Psoriasis area severity index increased 21.23 16.48 5 12759 183 90615500
Renal surgery 21.18 16.48 5 12759 185 90615498
Exposure during pregnancy 21.10 16.48 4 12760 238406 90377277
Intestinal anastomosis 21.04 16.48 7 12757 915 90614768
Joint swelling 20.98 16.48 24 12740 503276 90112407
Swelling 20.93 16.48 17 12747 419041 90196642
Frequent bowel movements 20.33 16.48 32 12732 56903 90558780
Systemic lupus erythematosus 20.26 16.48 13 12751 361883 90253800
Mycobacterium tuberculosis complex test positive 20.15 16.48 9 12755 2603 90613080
Ileal ulcer 20.05 16.48 7 12757 1059 90614624
Intentional dose omission 20.02 16.48 18 12746 17765 90597918
General physical health deterioration 19.55 16.48 13 12751 355102 90260581
Obstruction 19.52 16.48 10 12754 3911 90611772
B-cell type acute leukaemia 19.48 16.48 6 12758 613 90615070
Wheezing 19.05 16.48 5 12759 238075 90377608
Small intestinal resection 18.94 16.48 6 12758 672 90615011
Tuberculosis 18.85 16.48 15 12749 12534 90603149
Vocal cord leukoplakia 18.58 16.48 3 12761 13 90615670
Hidradenitis 18.55 16.48 10 12754 4337 90611346
Uterine leiomyoma 18.53 16.48 14 12750 10850 90604833
Intentional product use issue 18.44 16.48 4 12760 216888 90398795
Exposure via breast milk 17.93 16.48 8 12756 2307 90613376
Perineal disorder 17.63 16.48 3 12761 19 90615664
Pericarditis 17.61 16.48 8 12756 270143 90345540
Cholecystectomy 17.55 16.48 14 12750 11741 90603942
Somnolence 17.49 16.48 4 12760 209080 90406603
Neutropenia 17.47 16.48 5 12759 224899 90390784
Pseudopolyp 17.44 16.48 5 12759 399 90615284
Contraindicated product administered 17.25 16.48 12 12752 320127 90295556
Anastomotic stenosis 17.22 16.48 5 12759 417 90615266
Injection site papule 17.19 16.48 6 12758 906 90614777
Fibromyalgia 17.14 16.48 4 12760 206265 90409418
Spinal operation 17.08 16.48 13 12751 10183 90605500
Lower respiratory tract infection 17.01 16.48 7 12757 250652 90365031
Diverticulitis 16.97 16.48 26 12738 45161 90570522
Folliculitis 16.91 16.48 4 12760 204349 90411334
Dermatopathic lymphadenopathy 16.80 16.48 3 12761 26 90615657
Decreased appetite 16.74 16.48 17 12747 376523 90239160
Nephrolithiasis 16.71 16.48 27 12737 49058 90566625
Thrombosis prophylaxis 16.70 16.48 3 12761 27 90615656
Stress 16.68 16.48 36 12728 81359 90534324

FDA Adverse Event Reporting System (Male)

MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event
Ileostomy 149.89 17.97 38 10375 1080 42609842
Ileocaecal resection 123.99 17.97 27 10386 387 42610535
Psoriasis 123.19 17.97 99 10314 48505 42562417
Death 120.18 17.97 316 10097 470869 42140053
Ileal stenosis 112.79 17.97 34 10379 1850 42609072
Product storage error 104.24 17.97 52 10361 11088 42599834
Surgery 84.49 17.97 53 10360 17563 42593359
Intestinal obstruction 83.34 17.97 62 10351 27096 42583826
COVID-19 80.52 17.97 119 10294 115829 42495093
Stoma creation 73.12 17.97 14 10399 100 42610822
Drug ineffective 65.73 17.97 315 10098 629882 41981040
Colectomy 62.68 17.97 23 10390 2306 42608616
Small intestinal stenosis 61.59 17.97 18 10395 879 42610043
Dermatitis exfoliative generalised 59.88 17.97 29 10384 5795 42605127
Therapy interrupted 57.75 17.97 46 10367 22204 42588718
Therapeutic product effect decreased 52.64 17.97 56 10357 39094 42571828
Abdominal abscess 51.28 17.97 25 10388 5068 42605854
Ileectomy 50.35 17.97 11 10402 160 42610762
Angiolymphoid hyperplasia with eosinophilia 46.82 17.97 10 10403 130 42610792
Obstruction 46.23 17.97 20 10393 3083 42607839
Small intestinal obstruction 45.83 17.97 36 10377 17025 42593897
Gastrointestinal wall thickening 45.23 17.97 17 10396 1822 42609100
Gastrointestinal inflammation 44.62 17.97 22 10391 4570 42606352
Pruritus 42.10 17.97 121 10292 188650 42422272
Intestinal stenosis 41.54 17.97 18 10395 2786 42608136
Stenosis 39.56 17.97 16 10397 2085 42608837
Intestinal anastomosis 39.12 17.97 11 10402 467 42610455
Unevaluable event 39.09 17.97 45 10368 34243 42576679
Mycobacterium tuberculosis complex test positive 37.05 17.97 14 10399 1522 42609400
Osteosarcoma recurrent 36.58 17.97 8 10405 117 42610805
Arthralgia 35.98 17.97 121 10292 205117 42405805
Anastomotic stenosis 35.88 17.97 10 10403 411 42610511
Parenteral nutrition 35.62 17.97 11 10402 649 42610273
Small intestinal resection 35.31 17.97 11 10402 668 42610254
Abdominal pain 34.90 17.97 114 10299 190357 42420565
Proctectomy 34.87 17.97 8 10405 147 42610775
Product temperature excursion issue 34.46 17.97 10 10403 476 42610446
Intestinal resection 34.42 17.97 14 10399 1850 42609072
Lung neoplasm malignant 34.25 17.97 32 10381 19115 42591807
Prostate cancer 34.10 17.97 48 10365 44595 42566327
Basal cell carcinoma 33.20 17.97 34 10379 22699 42588223
Feeling of despair 32.77 17.97 12 10401 1196 42609726
Inflammation 31.37 17.97 40 10373 33807 42577115
Faecal calprotectin increased 30.58 17.97 15 10398 3079 42607843
Neutropenia 30.25 17.97 6 10407 199425 42411497
SARS-CoV-2 test positive 30.23 17.97 21 10392 8239 42602683
Colon cancer 29.45 17.97 22 10391 9659 42601263
Off label use 29.44 17.97 71 10342 638264 41972658
Knee arthroplasty 29.07 17.97 21 10392 8760 42602162
Skin plaque 29.00 17.97 18 10395 5845 42605077
Illness 28.89 17.97 33 10380 24897 42586025
Therapeutic response shortened 28.87 17.97 25 10388 13529 42597393
Laparotomy 28.70 17.97 8 10405 329 42610593
Ileocolostomy 27.01 17.97 5 10408 29 42610893
Postoperative abscess 26.77 17.97 8 10405 422 42610500
Tuberculosis 26.45 17.97 21 10392 10078 42600844
Hepatic cirrhosis 26.14 17.97 28 10385 19674 42591248
Acute kidney injury 25.96 17.97 31 10382 367306 42243616
Anastomotic ulcer 25.72 17.97 8 10405 483 42610439
Latent tuberculosis 25.68 17.97 11 10402 1654 42609268
Psoriatic arthropathy 25.53 17.97 31 10382 24936 42585986
Botryomycosis 25.39 17.97 5 10408 42 42610880
Skin burning sensation 25.00 17.97 18 10395 7469 42603453
Device issue 24.97 17.97 23 10390 13486 42597436
Thrombocytopenia 24.48 17.97 8 10405 190271 42420651
Ileal ulcer 24.21 17.97 9 10404 935 42609987
Somnolence 24.20 17.97 3 10410 141102 42469820
Peripheral arterial occlusive disease 24.12 17.97 17 10396 6821 42604101
Eczema 23.61 17.97 35 10378 34051 42576871
Jugular vein thrombosis 23.37 17.97 11 10402 2063 42608859
Abscess 22.06 17.97 22 10391 14226 42596696
Intestinal operation 21.98 17.97 6 10407 228 42610694
Rhinophyma 21.95 17.97 3 10410 0 42610922
Fistula 21.90 17.97 17 10396 7895 42603027
Enterocutaneous fistula 21.68 17.97 9 10404 1252 42609670
Colon operation 21.64 17.97 6 10407 242 42610680
Ostomy bag placement 21.49 17.97 4 10409 24 42610898
Therapeutic product effect incomplete 21.43 17.97 51 10362 70888 42540034
Neoplasm malignant 21.26 17.97 27 10386 22716 42588206
Prosthesis implantation 20.84 17.97 4 10409 29 42610893
Terminal ileitis 20.10 17.97 7 10406 603 42610319
Marginal zone lymphoma 20.03 17.97 5 10408 133 42610789
KL-6 increased 19.92 17.97 5 10408 136 42610786
Lung cancer metastatic 19.58 17.97 11 10402 2975 42607947
Cholangiocarcinoma 19.38 17.97 9 10404 1637 42609285
Frequent bowel movements 19.36 17.97 25 10388 21382 42589540
Myocardial infarction 18.99 17.97 70 10343 123939 42486983
Papillary cystadenoma lymphomatosum 18.95 17.97 4 10409 49 42610873
Dermatitis atopic 18.92 17.97 19 10394 12385 42598537
Confusional state 18.36 17.97 9 10404 167588 42443334
Squamous cell carcinoma 18.20 17.97 19 10394 12963 42597959
Hypereosinophilic syndrome 18.03 17.97 6 10407 450 42610472

FDA Adverse Event Reporting System (Geriatric)

MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event
COVID-19 270.71 15.49 253 16527 244807 110327712
Ileocaecal resection 216.41 15.49 42 16738 549 110571970
Therapy interrupted 195.10 15.49 111 16669 49711 110522808
Psoriasis 132.59 15.49 133 16647 139860 110432659
Intestinal obstruction 128.06 15.49 87 16693 53140 110519379
Death 127.68 15.49 308 16472 698561 109873958
Ileostomy 120.75 15.49 34 16746 2358 110570161
Ileal stenosis 118.77 15.49 36 16744 3234 110569285
Surgery 102.93 15.49 69 16711 41214 110531305
Colectomy 85.00 15.49 30 16750 4348 110568171
Abdominal abscess 74.14 15.49 33 16747 8786 110563733
Stenosis 72.91 15.49 25 16755 3326 110569193
Inflammatory bowel disease 70.36 15.49 30 16750 7204 110565315
Illness 65.08 15.49 71 16709 82100 110490419
Drug interaction 63.36 15.49 3 16777 500180 110072339
Unevaluable event 59.21 15.49 58 16722 59169 110513350
Abdominal pain 56.88 15.49 189 16591 512800 110059719
Urinary tract infection 56.33 15.49 141 16639 326141 110246378
Faecal calprotectin increased 56.03 15.49 25 16755 6694 110565825
Small intestinal obstruction 55.43 15.49 43 16737 32170 110540349
Intestinal stenosis 54.10 15.49 22 16758 4693 110567826
Stoma creation 53.59 15.49 11 16769 194 110572325
Product storage error 53.39 15.49 36 16744 21692 110550827
Angiolymphoid hyperplasia with eosinophilia 51.50 15.49 10 16770 131 110572388
Intestinal resection 50.87 15.49 20 16760 3909 110568610
Gastrointestinal inflammation 50.74 15.49 26 16754 9443 110563076
Small intestinal stenosis 50.03 15.49 15 16765 1298 110571221
Dermatitis exfoliative generalised 49.91 15.49 27 16753 10945 110561574
Ileectomy 49.49 15.49 11 16769 287 110572232
SARS-CoV-2 test positive 46.32 15.49 30 16750 16905 110555614
Gastrointestinal wall thickening 45.36 15.49 18 16762 3605 110568914
Small intestinal resection 43.41 15.49 13 16767 1120 110571399
Arthralgia 40.26 15.49 228 16552 779404 109793115
Anastomotic stenosis 40.21 15.49 11 16769 685 110571834
Osteosarcoma recurrent 38.61 15.49 8 16772 148 110572371
Skin plaque 38.57 15.49 24 16756 12621 110559898
Basal cell carcinoma 37.38 15.49 40 16740 45230 110527289
Proctectomy 37.30 15.49 9 16771 339 110572180
Intestinal anastomosis 36.93 15.49 11 16769 930 110571589
Prostate cancer 36.02 15.49 36 16744 37605 110534914
Anastomotic ulcer 35.38 15.49 11 16769 1075 110571444
Intervertebral disc protrusion 35.17 15.49 31 16749 27667 110544852
Neutropenia 33.23 15.49 8 16772 374612 110197907
Abortion spontaneous 33.19 15.49 33 16747 34249 110538270
Parenteral nutrition 33.08 15.49 10 16770 890 110571629
Postoperative abscess 32.86 15.49 10 16770 910 110571609
Hospitalisation 32.76 15.49 69 16711 142424 110430095
Pustule 32.33 15.49 14 16766 3490 110569029
Influenza 32.26 15.49 76 16704 169025 110403494
Intestinal operation 32.19 15.49 9 16771 608 110571911
Faecal calprotectin abnormal 32.08 15.49 8 16772 346 110572173
Off label use 31.80 15.49 119 16661 1500066 109072453
Hepatic steatosis 31.56 15.49 38 16742 48793 110523726
Dermatitis atopic 31.26 15.49 28 16752 25513 110547006
Cerebrovascular accident 30.88 15.49 78 16702 181206 110391313
Squamous cell carcinoma 30.37 15.49 24 16756 18439 110554080
Gallbladder operation 30.34 15.49 12 16768 2381 110570138
Prosthesis implantation 30.02 15.49 6 16774 92 110572427
Breast cancer female 29.07 15.49 20 16760 12448 110560071
Myocardial infarction 29.00 15.49 79 16701 192004 110380515
Diverticulitis 28.79 15.49 38 16742 53484 110519035
Confusional state 28.47 15.49 18 16762 468662 110103857
Device defective 28.01 15.49 13 16767 3809 110568710
Cellulitis 27.79 15.49 60 16720 125956 110446563
Stomatitis 27.74 15.49 4 16776 270238 110302281
Device issue 27.60 15.49 30 16750 34505 110538014
Rheumatoid arthritis 27.36 15.49 6 16774 299607 110272912
Somnolence 27.07 15.49 6 16774 297443 110275076
Lung cancer metastatic 26.85 15.49 13 16767 4185 110568334
Mycobacterium tuberculosis complex test positive 26.67 15.49 12 16768 3276 110569243
Thrombosis prophylaxis 26.23 15.49 5 16775 59 110572460
Neoplasm malignant 25.82 15.49 30 16750 37113 110535406
Nephrolithiasis 25.34 15.49 40 16740 66172 110506347
Sacroiliitis 24.75 15.49 13 16767 4965 110567554
Lung neoplasm malignant 24.64 15.49 28 16752 33814 110538705
Cholecystectomy 24.40 15.49 17 16763 10792 110561727
Peripheral arterial occlusive disease 24.30 15.49 16 16764 9264 110563255
Spinal operation 24.17 15.49 17 16763 10955 110561564
Malignant melanoma 23.66 15.49 20 16760 16871 110555648
Rhinophyma 23.38 15.49 3 16777 0 110572519
Terminal ileitis 23.31 15.49 9 16771 1675 110570844
Anal abscess 23.27 15.49 17 16763 11621 110560898
Cutaneous T-cell lymphoma 23.23 15.49 11 16769 3373 110569146
Anal fistula 23.14 15.49 15 16765 8458 110564061
Joint swelling 23.02 15.49 20 16760 442825 110129694
KL-6 increased 23.01 15.49 6 16774 311 110572208
Ear infection 22.78 15.49 37 16743 62695 110509824
Ileal ulcer 22.65 15.49 9 16771 1808 110570711
Pemphigus 22.43 15.49 3 16777 214567 110357952
Abscess 22.20 15.49 24 16756 27445 110545074
Colon cancer 22.08 15.49 19 16761 16424 110556095
Large intestinal stenosis 22.07 15.49 11 16769 3769 110568750
Hepatic cirrhosis 22.04 15.49 38 16742 67588 110504931
Cholangiocarcinoma 21.73 15.49 10 16770 2875 110569644
Breast cancer 21.71 15.49 28 16752 38514 110534005
Wheezing 21.57 15.49 6 16774 255224 110317295
Neuroendocrine tumour of the lung 21.41 15.49 4 16776 42 110572477
Infusion related reaction 21.33 15.49 16 16764 381146 110191373
Rectal stenosis 21.07 15.49 6 16774 433 110572086
Tuberculosis 20.80 15.49 19 16761 17755 110554764
Ostomy bag placement 20.77 15.49 4 16776 50 110572469
Thrombocytopenia 20.36 15.49 14 16766 348871 110223648
Papillary cystadenoma lymphomatosum 20.13 15.49 5 16775 213 110572306
Renal surgery 20.10 15.49 5 16775 214 110572305
Appendicitis 19.80 15.49 23 16757 28441 110544078
Colon operation 19.64 15.49 6 16774 553 110571966
Pruritus 19.57 15.49 153 16627 581407 109991112
Sinusitis 19.56 15.49 93 16687 296595 110275924
Marginal zone lymphoma 19.55 15.49 5 16775 240 110572279
Therapeutic product effect incomplete 19.24 15.49 76 16704 223729 110348790
Feeling of despair 19.12 15.49 10 16770 3788 110568731
Pityriasis rubra pilaris 18.94 15.49 5 16775 272 110572247
Botryomycosis 18.87 15.49 4 16776 83 110572436
Pustular psoriasis 18.84 15.49 16 16764 13589 110558930
Viral infection 18.83 15.49 31 16749 53108 110519411
Hidradenitis 18.82 15.49 11 16769 5169 110567350
Erythema nodosum 18.72 15.49 12 16768 6641 110565878
Psoriasis area severity index increased 18.63 15.49 5 16775 290 110572229
Cholelithiasis 18.56 15.49 34 16746 63388 110509131
Acrokeratosis paraneoplastica 18.55 15.49 3 16777 12 110572507
Jugular vein thrombosis 18.50 15.49 11 16769 5334 110567185
Mucous stools 18.40 15.49 12 16768 6835 110565684
Ileus 18.38 15.49 23 16757 30706 110541813
Face oedema 18.36 15.49 24 16756 33445 110539074
Pyoderma gangrenosum 18.25 15.49 11 16769 5465 110567054
Systemic lupus erythematosus 18.03 15.49 8 16772 254330 110318189
Medical device site inflammation 18.01 15.49 3 16777 15 110572504
Pelvic floor dysfunction 18.01 15.49 3 16777 15 110572504
Acute kidney injury 17.98 15.49 44 16736 635386 109937133
Obstruction 17.75 15.49 11 16769 5741 110566778
Cardiac disorder 17.59 15.49 37 16743 76243 110496276
Overdose 17.14 15.49 7 16773 233787 110338732
Small intestinal anastomosis 17.02 15.49 3 16777 22 110572497
Uterine leiomyoma 16.98 15.49 12 16768 7788 110564731
Frequent bowel movements 16.90 15.49 35 16745 71355 110501164
Osteochondrosis 16.71 15.49 8 16772 2513 110570006
Musculoskeletal stiffness 16.63 15.49 11 16769 279811 110292708
Fibromyalgia 16.48 15.49 3 16777 170906 110401613
Palmoplantar pustulosis 16.30 15.49 6 16774 980 110571539
Intra-abdominal fluid collection 16.28 15.49 9 16771 3805 110568714
Psoriatic arthropathy 16.25 15.49 66 16714 196695 110375824
Erythema 16.15 15.49 87 16693 291360 110281159
Folliculitis 16.04 15.49 3 16777 167650 110404869
Musculoskeletal pain 16.04 15.49 4 16776 183019 110389500
Inflammatory marker increased 16.03 15.49 15 16765 14454 110558065
Injection site papule 15.97 15.49 6 16774 1038 110571481
Skin burning sensation 15.79 15.49 18 16762 21807 110550712
Knee operation 15.75 15.49 11 16769 7011 110565508
Rash macular 15.68 15.49 24 16756 38662 110533857
Therapy cessation 15.66 15.49 26 16754 44831 110527688
Lithotripsy 15.62 15.49 3 16777 37 110572482
Myalgia 15.60 15.49 71 16709 222310 110350209
Pyelocaliectasis 15.56 15.49 6 16774 1113 110571406
Eye swelling 15.56 15.49 22 16758 33026 110539493

FDA Adverse Event Reporting System (Pediatric)

None

Pharmacologic Action:

SourceCodeDescription
ATC L04AC18 ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS
IMMUNOSUPPRESSANTS
IMMUNOSUPPRESSANTS
Interleukin inhibitors
FDA MoA N0000192798 Interleukin-23 Antagonists
FDA EPC N0000192799 Interleukin-23 Antagonist
CHEBI has role CHEBI:22587 antiviral agent
CHEBI has role CHEBI:50177 dermatologic drug
CHEBI has role CHEBI:50748 antipsoriatic
CHEBI has role CHEBI:65023 anti-asthmatic agent
CHEBI has role CHEBI:67079 anti-inflammatory agent

Related Drugs by ATC class:

L04AC Interleukin inhibitors 18 drugs
anakinrabasiliximabbimekizumabbrodalumabcanakinumabdaclizumabguselkumabixekizumabmirikizumabrilonaceptsarilumabsatralizumab show all 18 →

Drug Use | Suggest Off label Use Form| |View source of the data|

DiseaseRelationSNOMED_IDDOID
Psoriasis indication 9014002 DOID:8893
Palmoplantar pustulosis indication 27520001 DOID:4398
Crohn's disease indication 34000006
Psoriatic arthritis indication 156370009 DOID:9008
Plaque psoriasis indication 200965009
Pustular psoriasis indication 200973000
Erythrodermic psoriasis indication 200977004




🐶 Veterinary Drug Use

None

🐶 Veterinary products

None

Acid dissociation constants calculated using MoKa v3.0.0

None

Orange Book patent data (new drug applications)

None

Orange Book exclusivity data (new drug applications)

None

Bioactivity Summary:

TargetClassPharosUniProtActionTypeActivity value
(-log[M])		Mechanism
action		Bioact sourceMoA source
Interleukin-23 subunit alpha Cytokine INHIBITOR Kd 11 SCIENTIFIC LITERATURE DRUG LABEL

External reference:

IDSource
90ZX3Q3FR7 UNII
4038346 VANDF
C4505511 UMLSCUI
CHEBI:756510 CHEBI
CHEMBL3990029 ChEMBL_ID
DB14762 DRUGBANK_ID
D11052 KEGG_DRUG
10128 INN_ID
C000601773 MESH_SUPPLEMENTAL_RECORD_UI
8922 IUPHAR_LIGAND_ID
787732000 SNOMEDCT_US
787746000 SNOMEDCT_US
314451 MMSL
36772 MMSL
36774 MMSL
d09243 MMSL
017980 NDDF
2166040 RXNORM

Pharmaceutical products:

ProductCategoryIngredientsNDCFormQuantityRouteMarketingLabel
Skyrizi HUMAN PRESCRIPTION DRUG LABEL 1 0074-1050 INJECTION 150 mg SUBCUTANEOUS BLA 30 sections
Skyrizi HUMAN PRESCRIPTION DRUG LABEL 1 0074-2100 INJECTION 150 mg SUBCUTANEOUS BLA 30 sections
Skyrizi HUMAN PRESCRIPTION DRUG LABEL 1 0074-4059 INJECTION, SOLUTION 55 mg SUBCUTANEOUS BLA 30 sections
Skyrizi HUMAN PRESCRIPTION DRUG LABEL 1 0074-5015 INJECTION 600 mg INTRAVENOUS BLA 30 sections
Skyrizi HUMAN PRESCRIPTION DRUG LABEL 1 0074-8300 INJECTION 180 mg SUBCUTANEOUS BLA 30 sections
Skyrizi HUMAN PRESCRIPTION DRUG LABEL 1 0074-8350 INJECTION 180 mg SUBCUTANEOUS BLA 30 sections